LifeVantage (NASDAQ:LFVN – Get Free Report) announced its earnings results on Tuesday. The company reported $0.15 EPS for the quarter, hitting the consensus estimate of $0.15, Zacks reports. The firm had revenue of $47.21 million for the quarter. LifeVantage had a net margin of 1.47% and a return on equity of 27.85%. LifeVantage updated its FY 2025 guidance to 0.700-0.800 EPS.
LifeVantage Trading Down 0.4 %
Shares of NASDAQ LFVN traded down $0.05 during midday trading on Wednesday, reaching $12.93. The company’s stock had a trading volume of 228,284 shares, compared to its average volume of 60,322. LifeVantage has a fifty-two week low of $4.20 and a fifty-two week high of $14.71. The stock has a market capitalization of $164.22 million, a price-to-earnings ratio of 46.18 and a beta of 0.84. The stock has a 50 day simple moving average of $10.77 and a 200-day simple moving average of $8.31.
LifeVantage Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 17th. Stockholders of record on Monday, September 9th were issued a $0.04 dividend. The ex-dividend date was Monday, September 9th. This represents a $0.16 dividend on an annualized basis and a dividend yield of 1.24%. LifeVantage’s dividend payout ratio (DPR) is presently 57.14%.
About LifeVantage
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.
Read More
- Five stocks we like better than LifeVantage
- How Can Investors Benefit From After-Hours Trading
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- When to Sell a Stock for Profit or Loss
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Earnings Per Share Calculator: How to Calculate EPS
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for LifeVantage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeVantage and related companies with MarketBeat.com's FREE daily email newsletter.
